Spectrum: Local Antimicrobial Stewardship, for Markham Stouffville Hospital

Piperacillin-Tazobactam

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

General Spectrum of Activity

Antibiogram Data

Dosing

Renal

Adult

Usual dosage range: 4.5 g IV q8h

For coverage of *Pseudomonas aeruginosa:* 4.5 g q6h
(HAP or VAP dosing)

General Information

Common Usage

Common Usage

Broad spectrum agent with anti-pseudomonal activity.

Used for severe infections including:

  •  Pneumonia

  •  Intra-abdominal/hepatobiliary

  •  UTI

  •  Polymicrobial skin and soft tissue infection

  •  Febrile neutropenia

Adverse Effects

Adverse Effects

  • Allergy/rash (immediate or delayed)

  • Cytopenias- esp. thrombocytopenia

  • Eosinophilia

  • Interstitial nephritis

  • Abnormal liver enzymes

Major Interactions

Major Interactions

Avoid use with intravesicular BCG, Typhoid vaccine and Cholera vaccine due to decreased effect.

Increased levels of:

  • methotrexate

  • vancomycin

  • Vecuronium

  • Warfarin/Vitamin K antagonists

Decreased levels of:

  • aminoglycosides

  • mycophenolate

May result in false positive Coomb's test.
Tetracyclines may decrease levels of Piperacillin-Tazobactam.

Pharmacology

Pharmacology

Antimicrobial class: Ureidopenicillin with a beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Poor overall CSF penetration.
Moderate CNS penetration with inflamed meninges, may not be effective for P. aeruginosa.

Biliary penetration: Therapeutic